7.2. Analysis.
Comparison 7: Non‐serious adverse events: parallel‐group trials and first‐period cross‐over trials, Outcome 2: Subgroup analysis: proportion of participants with non‐serious adverse events according to dose
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.